1. Sign our petition calling on Cochrane to withdraw their review of Exercise Therapy for CFS here.
    Dismiss Notice
  2. Guest, the 'News in Brief' for the week beginning 8th April 2024 is here.
    Dismiss Notice
  3. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

Adverse events & deterioration reported by participants in the PACE trial of therapies for chronic fatigue syndrome, 2014, Sharpe,White,Chalder et al

Discussion in 'Psychosomatic research - ME/CFS and Long Covid' started by Sly Saint, May 9, 2021.

  1. Sly Saint

    Sly Saint Senior Member (Voting Rights)

    Messages:
    9,582
    Location:
    UK
    https://www.sciencedirect.com/science/article/pii/S0022399914001883?via=ihub

    (was this data ever released?)
     
    alktipping, Michelle, Andy and 2 others like this.
  2. cassava7

    cassava7 Senior Member (Voting Rights)

    Messages:
    985
    From the discussion of the reanalysis of the PACE trial, which cited this paper (spacing mine):

    Turning now to safety issues, there were few group differences in the incidence of adverse events, and the researchers concluded that both CBT and GET were safe for people with CFS. This finding – particularly that relating to GET - contrasts markedly with findings from informal surveys conducted by patient organisations [38, 39].

    In these surveys, between 33% and 79% of respondents report worsened health as a result of having participated in some form of graded exercise programme (weighted average across 11 different surveys: 54% [39]). Of course, in such surveys, participant self-selection may operate to enhance the reporting rates for adverse outcomes. However, this finding is so consistent, and the number of participants surveyed is so large (upwards of 10,000 cases), that it cannot be entirely dismissed.

    One likely reason for the discrepancy between PACE’s findings and those of patient surveys is the conservative approach used in PACE’s GET programme. Patients were encouraged to increase activity only if it provoked no more than mild symptoms [40]. Unfortunately, compliance with the activity recommendations was not directly assessed: actigraphy data were collected only at trial commencement [1] and never reported. This is a significant omission, since there is evidence that graded exercise therapies are not always successful in actually increasing CFS patients’ activity levels [41]. Even those who comply with exercise goals may reduce other activities to compensate [42]. The lack of improvement in fitness levels in PACE’s GET group does suggest that participants may not have substantially increased their activity levels, even over the course of an entire year.

    Also, even though the majority of GET participants chose walking as their primary activity [2], this group demonstrated an average increase in walking speed of only 10% after an entire year (increases of 50% or more have been observed in other patient populations [35]). Given these features, it is inappropriate to generalise the safety findings from PACE to graded activity programmes more widely, especially as they are currently implemented in clinical settings.​
     
    Woolie, Mithriel, Lidia and 8 others like this.

Share This Page